Complex analysis of the TP53 tumor suppressor in mantle cell
and diffuse large B-cell lymphomas

J 2017

Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas

ZLÁMALÍKOVÁ, Lenka, Mojmír MOULIS, Barbora RAVČUKOVÁ, Květoslava LIŠKOVÁ, Jitka MALČÍKOVÁ et. al.

Basic information

Original name

Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas

Authors

ZLÁMALÍKOVÁ, Lenka (203 Czech Republic), Mojmír MOULIS (203 Czech Republic), Barbora RAVČUKOVÁ (203 Czech Republic), Květoslava LIŠKOVÁ (203 Czech Republic), Jitka MALČÍKOVÁ (203 Czech Republic), David ŠÁLEK (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, guarantor, belonging to the institution), Miluše SVITÁKOVÁ (203 Czech Republic), Renata HRABÁLKOVÁ (203 Czech Republic), Jan ŠMARDA (203 Czech Republic) and Jana ŠMARDOVÁ (203 Czech Republic)

Edition

Oncology Reports, ATHENS, SPANDIDOS PUBL LTD, 2017, 1021-335X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.976

RIV identification code

RIV/00216224:14110/17:00097935

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3892/or.2017.5891

UT WoS

000411688200073

Keywords in English

mantle cell lymphoma; diffuse large B-cell lymphoma; p53 tumor suppressor; FASAY; TP53 mutation

Abstract

V originále

Mutations and deletions of the tumor suppressor TP53 gene are the most frequent genetic alterations detected in human tumors, though they are rather less frequent in lymphomas. However, acquisition of the TP53 mutation was demonstrated to be one of the characteristic markers in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) and prognostic value of the TP53 status has been recognized for these diseases. We present the complex analysis of the TP53 aberrations in 57 cases of MCL and 131 cases of DLBCL. The TP53 status was determined by functional analyses in yeast (FASAY) followed by cDNA and gDNA sequencing. The level of the p53 protein was assessed by immunoblotting and loss of the TP53-specific locus 17p13.3 was detected by FISH. Altogether, we detected 13 TP53 mutations among MCL cases (22.8%) and 29 TP53 mutations in 26 from 131 DLBCL cases (19.8%). The ratio of missense TP53 mutations was 76.9% in MCL and 82.8% in DLBCL. The frequency of TP53 locus deletion was rather low in both diseases, reaching 9.3% in MCL and 15.3% in DLBCL. The presence of TP53 mutation was associated with shorter overall survival (OS) and progression-free survival (PFS) in MCL. Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease.

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

ZLÁMALÍKOVÁ, Lenka, Mojmír MOULIS, Barbora RAVČUKOVÁ, Květoslava LIŠKOVÁ, Jitka MALČÍKOVÁ, David ŠÁLEK, Jiří JARKOVSKÝ, Miluše SVITÁKOVÁ, Renata HRABÁLKOVÁ, Jan ŠMARDA and Jana ŠMARDOVÁ. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas. Oncology Reports. ATHENS: SPANDIDOS PUBL LTD, 2017, vol. 38, No 4, p. 2535-2542. ISSN 1021-335X. Available from: https://dx.doi.org/10.3892/or.2017.5891.

@article{1392780,
   author = {Zlámalíková, Lenka and Moulis, Mojmír and Ravčuková, Barbora and Lišková, Květoslava and Malčíková, Jitka and Šálek, David and Jarkovský, Jiří and Svitáková, Miluše and Hrabálková, Renata and Šmarda, Jan and Šmardová, Jana},
   article_location = {ATHENS},
   article_number = {4},
   doi = {http://dx.doi.org/10.3892/or.2017.5891},
   keywords = {mantle cell lymphoma; diffuse large B-cell lymphoma; p53 tumor suppressor; FASAY; TP53 mutation},
   language = {eng},
   issn = {1021-335X},
   journal = {Oncology Reports},
   title = {Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas},
   url = {https://www.spandidos-publications.com/10.3892/or.2017.5891},
   volume = {38},
   year = {2017}
}

TY  - JOUR
ID  - 1392780
AU  - Zlámalíková, Lenka - Moulis, Mojmír - Ravčuková, Barbora - Lišková, Květoslava - Malčíková, Jitka - Šálek, David - Jarkovský, Jiří - Svitáková, Miluše - Hrabálková, Renata - Šmarda, Jan - Šmardová, Jana
PY  - 2017
TI  - Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas
JF  - Oncology Reports
VL  - 38
IS  - 4
SP  - 2535-2542
EP  - 2535-2542
PB  - SPANDIDOS PUBL LTD
SN  - 1021335X
KW  - mantle cell lymphoma
KW  - diffuse large B-cell lymphoma
KW  - p53 tumor suppressor
KW  - FASAY
KW  - TP53 mutation
UR  - https://www.spandidos-publications.com/10.3892/or.2017.5891
N2  - Mutations and deletions of the tumor suppressor TP53 gene are the most frequent genetic alterations detected in human tumors, though they are rather less frequent in lymphomas. However, acquisition of the TP53 mutation was demonstrated to be one of the characteristic markers in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) and prognostic value of the TP53 status has been recognized for these diseases. We present the complex analysis of the TP53 aberrations in 57 cases of MCL and 131 cases of DLBCL. The TP53 status was determined by functional analyses in yeast (FASAY) followed by cDNA and gDNA sequencing. The level of the p53 protein was assessed by immunoblotting and loss of the TP53-specific locus 17p13.3 was detected by FISH. Altogether, we detected 13 TP53 mutations among MCL cases (22.8%) and 29 TP53 mutations in 26 from 131 DLBCL cases (19.8%). The ratio of missense TP53 mutations was 76.9% in MCL and 82.8% in DLBCL. The frequency of TP53 locus deletion was rather low in both diseases, reaching 9.3% in MCL and 15.3% in DLBCL. The presence of TP53 mutation was associated with shorter overall survival (OS) and progression-free survival (PFS) in MCL. Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease.
ER  -

ZLÁMALÍKOVÁ, Lenka, Mojmír MOULIS, Barbora RAVČUKOVÁ, Květoslava LIŠKOVÁ, Jitka MALČÍKOVÁ, David ŠÁLEK, Jiří JARKOVSKÝ, Miluše SVITÁKOVÁ, Renata HRABÁLKOVÁ, Jan ŠMARDA and Jana ŠMARDOVÁ. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas. \textit{Oncology Reports}. ATHENS: SPANDIDOS PUBL LTD, 2017, vol.~38, No~4, p.~2535-2542. ISSN~1021-335X. Available from: https://dx.doi.org/10.3892/or.2017.5891.

Detailed Information on Publication Record